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ICON-6: the danger of changing study design midstream
Jonathan Ledermann and colleagues1,2 report the ICON-6 
randomised trial ﬁ ndings for the tyrosine kinase inhibitor 
cediranib in relapsed platinum-sensitive ovarian cancer. 
Cediranib oﬀ ered the prospect of improved eﬃ  cacy 
with tolerable side-eﬀ ects, and ICON-6 was a pragmatic 
trial to provide real-world evidence of the eﬀ ectiveness, 
safety, and acceptability of cediranib plus chemotherapy 
(either concurrent or concurrent plus maintenance as 
long as patients were deriving beneﬁ t), compared with 
chemotherapy plus placebo. ICON-6 found ”meaningful 
improvement in progression free survival”2 (hazard 
ratio 0·56, 95% CI 0·44–0·72) for concomitant plus 
maintenance cediranib compared with placebo, as well as 
signiﬁ cantly more diarrhoea, hypothyroidism, and voice 
changes. However, after unexpected and major design 
changes were enforced, we still await data for overall 
survival; the safety data are less informative than might be 
necessary, and there are no convincing data yet for patient 
acceptability and quality of life, which can be particularly 
relevant to inform trade-oﬀ s between improved eﬃ  cacy 
and increased side-eﬀ ects. These design changes should 
not have been necessary, and clinical trials should be 
better structured to make sure this does not recur.
The original study design promised more relia ble 
evidence, but instead of randomly assigning roughly 
2000 participants, the study underwent a major revision 
with just 387 participants randomly assigned because 
the drug company involved (AstraZeneca) decided 
(on Sept 14, 2011) to cease commercial development 
of cediranib, owing to negative ﬁ ndings for overall 
survival in three pivotal phase 3 studies on diﬀ erent 
cancers.3–5 With insuﬃ  cient remaining drug stock and its 
short shelf life, as well as AstraZeneca being unwilling 
to manufacture additional supplies, a fundamental 
redesign (or complete abandonment) became necessary.
The researchers, in partnership with the independent 
Data Monitoring Committee (iDMC), and the funders 
should be congratulated on having the vision and 
creativity to redesign the study, within the constraints 
of the remaining drug available. They redeﬁ ned the 
primary outcome from overall survival to progression-
free survival, focused on comparing concomitant plus 
maintenance cediranib with placebo, and reduced power 
from 90% to 80%, with overall survival, toxic eﬀ ects, 
and quality of life becoming secondary outcomes. This 
change meant that a revised sample size of 440 patients 
(for those on cediranib, 20 mg after the initial 30 mg 
dose was dropped) was used. The study ﬁ nally randomly 
assigned 486 patients, of whom 456 receiving the 
20 mg dose were analysed.
Designing and executing large multinational trials is 
challenging, with many stakeholders (patients, clinicians, 
funders, regulators, ethics committee members, drug 
companies, health-care providers) to accommodate and 
many reasons for why a study might not be completed 
as planned (stopping early for safety, eﬃ  cacy, or so-called 
futility reasons). Over the past few decades, statistical 
methods for sequential6 and Bayesian designs7 and more 
recently a plethora of innovative adaptive designs,8 
coupled with improved remits and increased experience 
within iDMCs, and funders looking for better and more 
eﬃ  cient designs, have allowed clinical trialists to deliver 
more eﬃ  cient and responsive clinical trials. So there are 
many legitimate reasons to redesign or terminate trials on 
scientiﬁ c grounds, and well established statistical methods 
to achieve this in an orderly fashion. However, having to 
terminate or majorly redesign a trial because a stakeholder 
decides to cease manufacturing the relevant drug is not, in 
our view, a legitimate reason—from a scientiﬁ c perspective 
insight is lost into that compound and mechanism of 
action, and we are letting down participants who agree 
to take part in research by allowing this to happen. 
When trials are redesigned midstream, there are ethical 
challenges in consenting future participants, and also 
potentially re-consenting those recruited under the 
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In The Lancet, Fred Lublin and colleagues1 report 
negative results of a randomised, double-blind trial 
(INFORMS) assessing the eﬃ  cacy of ﬁ ngolimod, 
an oral sphingosine 1-phosphate receptor (S1PR) 
modulator, on disability progression in patients with 
primary progressive multiple sclerosis. This result is 
particularly disappointing because no US Food and Drug 
Administration (FDA)-approved disease-modifying 
therapies exist for primary progressive multiple sclerosis 
at present. In contrast to drastic advances during 
the past 20 years in treatment of relapsing multiple 
sclerosis, the number of unsuccessful studies in primary 
progressive multiple sclerosis is substantial. This poor 
record reﬂ ects the fact that the cellular and molecular 
mechanisms underlying clinical progression in multiple 
sclerosis are poorly understood.
Primary progressive multiple sclerosis—why we are failing
original process of informed consent, to make sure the 
participants are properly aware of the reasons for the 
redesign and the scientiﬁ c value of the new study. Here, 
the redesign was driven by the cessation of manufacture 
of the drug, but likewise a public funder might withdraw 
support for a study midstream due to a change in policy 
or a re-assessment of the evidence value for the health-
care system. Often, it is just as valuable to know with good 
precision that an intervention doesn’t work, particularly if 
it is expensive or associated with considerable side-eﬀ ects.
Most importantly, we must do everything we can as 
clinical trialists to reassure the patients and the public 
that their participation is always considered with 
the utmost care and constant vigilance around the 
emerging risk–beneﬁ t ratio, and never taken for granted. 
To get patients to participate in research is already 
challenging, and we are too permissive of stakeholders 
changing their minds midstream. This issue could 
be avoided by requiring all stakeholders to commit 
to seeing the study through, backed by the required 
resources to complete this study (and with adequate 
insurance cover for the case of commercial failure), 
with subsequent changes to design only occurring 
through agreed scientiﬁ c criteria mediated through 
appropriate statistical procedures. We owe participants 
this protection to properly safeguard their contribution, 
as well as improving the scientiﬁ c yield of our trials.
Interestingly, after the initial conference presentation1 
of the potentially positive ﬁ ndings in 2013, and more 
recent promising early phase ﬁ ndings,9 interest from 
AstraZeneca appears to have been rekindled, and after 
company review of the outcomes and survival methods, 
the possibility now exists of using these data for 
regulatory submission. However, these data will obviously 
be less convincing for that purpose than if the trial had 
continued under its original design—in terms of evidence 
of eﬀ ectiveness, safety, and acceptability. It appears to us 
that now this situation has been fully played out, no one 
has gained any advantage from the 2011 decision to stop 
manufacturing cediranib. We should try hard to make 
sure—particularly for the sake of patients—that this type 
of avoidable problem isn’t allowed to happen again.
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